Booth to discuss latest results on METAglut1™ at the meeting of SENP 2018
April 27, 2018
Booth at the European Conference on Glut1 Deficiency 2018
June 22, 2018
June 11, 2018.
[AWARDS] Company ; METAglut1™
As a company developing diagnostic tests to detect abnormalities in cellular energetics, we are today announcing that we have received an European grant of €3.2 million ($3.75M) as part of the phase 2 of the European Commission’s H2020 SME Instrument Program.
This grant will allow us to accelerate our clinical and regulatory development pathways.
In the third quarter of 2018 we will be launching a large-scale prospective validation study of METAglut1™, our test to aid the early diagnosis of De Vivo disease also known as Glut1 Deficiency Syndrome (Glut1DS).
We already have obtained the necessary authorizations for this study from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP). The study will be carried out in collaboration with more than 40 neurology centers in France, including the Pitié Salpêtrière and Robert Debré (AP-HP) hospitals, and Laboratoire Cerba. It will last until 2020, with the results expected to be published early 2021.
